Author

James Kearns

Observed names: J. Kearns, James E. Kearns

Observed institution: Tufts Medical Center

OpenAlex ID: A5111432810

Self‐Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy

2019 · William E. Grizzle, Rick A. Kittles, et al. · Cancer Medicine · 15

PDF

Satisfying the fatty acid demand of prostate cancer: De novo synthesis versus uptake as alternative and potentially cooperative prostate cancer phenotypes.

2017 · Sandra Marlene Gaston, James Kearns, et al. · Journal of Clinical Oncology · 3

P439 – From retention to relief: Cohort characteristics and outcomes for men with urinary retention undergoing aquablation: An analysis of the International Collaborative Aquablation Research Urology Society (ICARUS) database

2025 · R. Foucault, D. Bouhadana, et al. · European Urology · 1

Mp36-08 What Are Rates of Incidental Prostate Cancer Detected During Aquablation?

2025 · David J. Nusbaum, Gregory Raster, et al. · The Journal of Urology

Pd08-01 Global Aquablation Experience From the Icarus (international Collaborative Aquablation Research Urology Society) Database: Largest Cohort Assessing Efficacy and Safety in Benign Prostatic Hyperplasia Treatment

2025 · Adel Arezki, Kevin C. Zorn, et al. · The Journal of Urology

Ip03-02 From Retention to Relief: Cohort Characteristics and Outcomes for Men With Urinary Retention Undergoing Aquablation: an Analysis of the International Collaborative Aquablation Research Urology Society (icarus) Database

2025 · Rosie Foucault, David Bouhadana, et al. · The Journal of Urology

Ip19-17 Evaluating Bleeding Risk and Clinical Outcomes With Perioperative Antithrombotics in Aquablation: an Analysis of the International Collaborative Aquablation Research Urology Society (icarus) Database

2025 · Jeffrey A. Sioufi, David Bouhadana, et al. · The Journal of Urology

Ip03-05 Real-world Outcomes of Aquablation for Bph: Comparison With Pivotal Water Trials in Diverse Patient Populations

2025 · Alexander Paulglaser, James Kearns, et al. · The Journal of Urology

Ip19-14 Aquablation for Benign Prostatic Hyperplasia and Prostate Cancer: a Safe and Effective Treatment Option

2025 · Adel Arezki, Kevin C. Zorn, et al. · The Journal of Urology

A0807 – Evaluating bleeding risk and clinical outcomes with perioperative antithrombotics in aquablation: An analysis of the International Collaborative Aquablation Research Urology Society (ICARUS) database

2025 · J. Sioufi, D. Bouhadana, et al. · European Urology

A0806 – Comparative outcomes of aquablation for benign prostatic hyperplasia: An analysis of men with bladder stones

2025 · J. Cabral, M. Gannon, et al. · European Urology

Mp30-20 Prostate Biopsy Over-reads at High Volume, Academic Cancer Centers Are Inexpensive and Optimize Treatment Pathways

2021 · Blair Townsend, Caroline Miller, et al. · The Journal of Urology

Pd10-04 Beating the System? Comparing Detection Rates of Prostate Cancer in Mri-ultrasound Fusion Biopsies and Systematic Prostate Biopsies

2021 · Caroline Lu, Emily Roebuck, et al. · The Journal of Urology

Abstract 1933: Tissue print Vmemimaging: Visualizing bioelectric signatures in cancer

2019 · Dany S. Adams, Brian H. Tracey, et al. · Tumor Biology

Mp24-05 Self-identified African Americans and Prostate Cancer Risk: West African Genetic Ancestry Is Associated With Prostate Cancer Diagnosis and With Higher Gleason Sum on Biopsy

2019 · Sandra Gaston*, Rick Kittles, et al. · The Journal of Urology

Abstract 372: Obesity matters: Prostate cancers that overexpress fatty acid binding protein 5 are more common in men who are overweight or obese

2018 · Sandra M. Gaston, Soroush Rais-Bahrami, et al. · Cancer Research

Mp29-15 Make It From Scratch or Have It Delivered? Satisfying the Fatty Acid Demand of Prostate Cancer

2018 · Sandra Gaston, Soroush Rais-Bahrami, et al. · The Journal of Urology

Pd20-01 When Can Active Surveillance (as) Be Less Active? Prediction of Long-term Non-reclassification for Men With Low-risk Prostate Cancer

2018 · Matthew Cooperberg, Anna Faino, et al. · The Journal of Urology

PDF

Abstract 2209: Characterization of FABP5 antibodies in prostate

2017 · Dennis A. Otali, Denise K. Oelschlager, et al. · Cancer Research

Abstract 457: Satisfying the fatty acid demand of prostate cancer: Outlier overexpression of genes involved in de novo synthesis vs fatty acid uptake define two different and potentially synergistic prostate cancer phenotypes

2017 · Sandra M. Gaston, James Kearns, et al. · Cancer Research

Mp43-10 the Role of Surveillance Biopsy With No Cancer as a Prognostic Marker for Reclassification: Results From the Canary Prostate Active Surveillance Study (pass)

2017 · James Kearns, Anna Faino, et al. · The Journal of Urology

PDF

Pd55-02 the Use of Five-alpha Reductase Inhibitors and Their Association With Reclassification and Pathologic Outcomes in the Canary Prostate Active Surveillance Study (pass)

2017 · James Kearns, Anna Faino, et al. · The Journal of Urology

Abstract C40: A biopsy-focused approach to molecular studies of prostate cancer in African Americans: the Birmingham Alabama Prostate Cancer Consortium (BAPrCa)

2017 · Sandra M. Gaston, Dennis Otali, et al. · Cancer Epidemiology Biomarkers & Prevention

Abstract 20: Outlier overexpression of genes involved in fatty acid metabolism and processing define two aggressive prostate cancer phenotypes

2016 · Sandra M. Gaston, Kerry Dehimer, et al. · Cancer Research

Mp1-20 Distinguishing Indolent From Aggressive Prostate Cancer in Active Surveillance Using Partialwave Spectroscopy to Measure Nanocytological Field Carcinogenesis

2015 · James Kearns, Brian Helfand, et al. · The Journal of Urology

Works count: 27

Citation count: 19

H-index: 2

I10-index: 1